BrainStorm’s NurOwn Gets Many, Many Thumbs Down From US FDA Panel

 
• By Sue Sutter
Magic hat
Adcomm members were not persuaded by what one panelist called BrainStorm's 'statistical magic' on the failed Phase III trial. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers